Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine, or 4-AP). Data collected in laboratory studies found that Fampridine-SR can improve the communication between damaged nerves, which may result in increased neurological function.
Adobe Acrobat Reader required, click here to download
--------------------------------------------------------
--------------------------------------------------------
Mechanism of Action for Fampridine-SR
Click here for the Mechanism of Action video for Fampridine-SR
Click here for the Mechanism of Action video for Fampridine-SR
Additionally, Acorda Therapeutics® is a biotechnology company whose mission is to develop and market therapies to restore neurological function in people with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system. Acorda’s marketed products include Zanaflex Capsules® (tizanidine hydrochloride) and Zanaflex® (tizanidine hydrochloride) tablets. Zanaflex Capsules and Zanaflex are short-acting drugs approved for the management of spasticity. Because of the short duration of effect, treatment should be reserved for those daily activities and times when relief of spasticity is most important. The most frequent adverse events with these products are dry mouth, sedation, asthenia, and dizziness, and are most often considered mild to moderate. For full prescribing information click here.
For more information, visit the Acorda Therapeutics website
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
0 comments:
Post a Comment